〔記者陳永吉／台北報導〕高端疫苗研發的國產武漢肺炎（COVID-19）疫苗，昨正式揭露二期臨床試驗結果，數據都達成當初預設的目標之上，兩大指標的安全性與免疫生成性數據表現良好。高端總經理陳燦堅表示，對於拿到食藥署核准緊急使用授權（EUA）樂觀期待，拚七月可提供國人開打。
安全性、免疫生成性…
2期解盲成功// 高端拚EUA 7月開打
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |